C.R. Bard, Inc. v. AngioDynamics, Inc., No. 23-2056 (Fed. Cir. Dec. 15, 2025)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

This case comes back to us after a retrial in the U .S. District Court for the District of Delaware in which a jury found that AngioDynamics, Inc. (“AngioDynamics”) will- fully infringed asserted claims of Bard Peripheral Vascu- lar, Inc. ’s (“Bard’s”) U.S. Patents 8,475,417 (“the ’417 patent”), 8,545,460 (“the ’460 patent”), and 8,805,478 (“the ’478 patent”), and that the asserted claims were not inva- lid.